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Abstract 
 
This paper provides a detailed description of the New Zealand biotechnology sector 
based on a re-analysis of the first comprehensive (1998/99) survey of biotechnology 
in New Zealand, data from an original (2002) survey conducted by the author and a 
detailed review of secondary sources. It provides the background for a study of the 
determinants of innovation reported elsewhere (Marsh, 2004).  
A review of alternative data sources on sector size and characteristics is followed 
by a comparison of New Zealand and international biotech indicators. Data is 
presented on enterprise type and size and the age distribution of New Zealand biotech 
enterprises. This is followed by an analysis of innovative output using data on new 
products, processes and patents. Data is also presented on partnerships and alliances, 
information sources and other factors affecting innovative performance. 
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Biotechnology in New Zealand 
Selected Highlights 
Sector Characteristics 
• In 1998/99 New Zealand’s modern biotech ‘sector’ consisted of 
approximately 57 enterprises, employing  around 1700 people (the modern 
biotech ‘sector’ is defined here as the population of private and public sector 
enterprises that carry out modern biotech R&D).  
• They reported expenditure on biotech of NZ$202 million and income from 
biotech of NZ$236 million for 1998/99. This compares to enterprise income 
from all sources of NZ$2.1 billion i.e. biotech provided around 11% of 
income for the 57 enterprises.  
• Data from the 2002 survey indicates that annual growth in expenditure may 
be as high as 20%. 
• Most activity is concentrated in universities, Crown Research Institutes 
(CRI) and a small number of private sector companies e.g. Genesis, 
Virionyx, ViaLactia. 
• Enterprises in the modern biotech sector are split fairly evenly between the 
private sector and the public sector.  
 
Research and Development 
• Respondents to the 2002 biotech survey indicated that R&D constituted 
around 10% of total expenditure. 
• Expenditure on biotech R&D comprised around 80% of all biotech 
expenditure.  
• Around 60% of all ‘biotech staff’ were engaged in R&D.  
• Respondents spent far more on R&D than the industry average. For example 
the dairy industry is reported to spend around 1% of turnover on R&D, 
while R&D expenditure as a proportion of value added of manufactured 
products was 1.3 percent in 1999/2000. 
 
Development of the NZ Biotech Industry 
• Data on the age distribution of biotech process use provides useful 
information on the development of the biotech industry over time and may 
also be compared with similar data from overseas.  
• Average age in use in New Zealand is longer than in Canada for all but two 
process categories, possibly because of the lower number of new entrants in 
New Zealand.  
• There are distinct differences between modern and older biotechnology 
processes. Genomics exhibits a typical age structure for a recent process; 
56% have used this process for 5 years or less, 83% have used it for 10 years 
or less.  
• Extraction/purification/separation is typical of a more mature technology; 
24% started using this process within the last 5 years (often these are new 
enterprises). A further 24% have been using this process for at least 20 
years. 
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Biotech Alliances 
• Most enterprises (84%) responding to the 2002 biotech survey had at least 
one alliance involving biotech activity. 
• 62% reported at least one New Zealand alliance while 41% reported an 
overseas alliance.  
• Overseas alliances were most common in the tertiary education, and 
scientific research groups.  
• The most commonly reported alliance purposes were product/process 
development; reported by 82% of respondents who had an alliance and basic 
research.  
• Respondents were asked to rate ‘partnership outcomes to date’; 50% were 
described as ‘very productive’ and 44% as ‘somewhat productive’. Only 6% 
were reported to be ‘not very/not at all productive’.  
 
Innovative Output 
• One indication of the rate of innovation by biotech respondents is provided 
by questions such as: “In the last 3 years, how many new or significantly 
improved products or processes has this business introduced on to the 
market?”  
• Overall, 51% of respondents to the 2002 biotech survey reported 
implementation of a new product with the innovation rate being lowest for 
food manufacturers (33%) and highest for non-food manufacturers (79%).  
• Process innovation rates were much lower with only 21% reporting 
implementation of a new process in the last 3 years; this is notably different 
to the 1998/99 survey when 33% of enterprises reported introduction of new 
products and the same percentage reported introduction of new processes.  
• New Zealand biotech firms do not appear to have a particularly high rate of 
new product or process development relative to other New Zealand sectors 
or to other countries. 
 
Patenting 
• New Zealand’s rate of modern biotech patent applications over the five 
years to the end of 2002 was 3.7 per million of population, per year. This is 
below the average for the G7 (5.3) and for a reference group of small, 
developed OECD economies (5.5).  
• Overall New Zealand ranks eleventh out of 18 with a patenting rate above 
that found in France and Japan.  
• New Zealand’s performance is disappointing compared to other small 
countries with strong primary industries that it might hope to emulate e.g. 
Denmark (15.2), Switzerland (10.9), Netherlands (5.5), Australia (4.1). 
• Comparison of the three-year periods 1997-99 and 2000-02 reveals an 
average increase in patenting rates of 51%. New Zealand has increased its 
performance relative to the OECD and Australia; although the rapid change 
in patent application rates may, in part reflect an increased propensity to 
patent in universities and Crown Research Institutes. 
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International Comparisons 
• The OECD has taken the lead in attempting to develop internationally 
comparable statistics on biotechnology but the variety of definitions and 
data collection methods make reliable comparisons almost impossible.  
• In the OECD’s ‘2003 Scoreboard’, New Zealand is reported to put the 
highest proportional effort into biotech R&D (biotech R&D as a proportion 
of total R&D). This results both from New Zealand’s R&D specialisation in 
the primary sector and from use of a broad definition of what constitutes 
biotech R&D.  
• However New Zealand’s total government expenditure on biotech R&D is 
the third smallest of the 21 countries listed. 
• A more accurate international comparison can be made with Canada, based 
on data from the Statistics New Zealand biotech survey, since this was 
closely modelled on surveys carried out by Statistics Canada.  
• New Zealand’s biotech revenue per million population (NZ$54 million) is 
lower than Canada's (NZ$94 million), but the difference is fairly small 
considering Canada’s higher per capita income and proximity to the United 
States.  
• New Zealand has a lower mean revenue per biotech firm (NZ$5.3m vs. 
NZ$8.0m); consistent with the predominance of small firms in the New 
Zealand economy.  
• New Zealand appears to have a significantly higher rate of biotech 
employment.  
• There is some evidence that use of biotech processes in New Zealand is at an 
earlier stage with 72% being at the R&D stage against 49% in Canada. 
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Department of Economics, University of Waikato 21/9/2004 
1 Introduction 
Despite the small size of its economy and of its science base New Zealand has had 
a significant role in the development of modern biotechnology. Indeed a New 
Zealand born biophysicist, Dr Maurice Wilkins assisted at the birth of modern 
biotechnology through the first description of the structure of DNA. Wilkins was 
later jointly awarded the Nobel Prize for this work together with Crick and 
Watson.  
 
Much of New Zealand’s work builds on national strengths in agricultural and 
primary industry production and research. But there are also a number of new 
enterprises at the forefront of research in health and in intellectual property. 
Recent examples cited by the industry organisation BIOTENZ (1998) include: 
breeding of transgenic crops; clonal afforestation; genetic manipulation of flower 
colour; the world's first enteric bacteria-based bio insecticide; a project to map the 
sheep genome; the world's first sheep genetically engineered for increased wool 
production; and the world's first recombinant livestock vaccine to combat sheep 
measles. More recently the report of the biotechnology taskforce noted that:  
New Zealand has significant strengths in large animal biology (in 
particular being world leading in overall knowledge of the sheep and dairy 
cow), as well as having world-class research teams in a number of areas of 
biomedical science and bioengineering. More recently New Zealand has 
also emerged as world leading in some areas of enabling technology, 
which is technology that allows both novel and intensive data collection 
(Biotechnology Taskforce, 2003, p. 23). 
Most modern biotechnology activities in New Zealand are concentrated in 
universities and Crown Research Institutes (CRI) and a small number of private 
sector companies e.g. Genesis, Virionyx, ViaLactia. The government has been 
estimated to spend around NZ$127m per year on biotechnology-related research 
(Ogilvie, 2003), ranging from genomics to processing of natural products 
including about NZ$18 million on research involving genetic modification 
(Wright, 2000, p.7). Biotechnology-related research comprises around 19% of 
total government R&D spending ($677 million in 2002/20031), making New 
                                                 
1 See Ministry of Research Science and Technology. (2002). Briefing to the Incoming Minister of 
Research, Science and Technology. 
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Zealand one of three OECD countries with a share above 10% (OECD, 2003). 
Genesis has invested over NZ$80 million in research since its inception in 1994 
while CRIs and companies such as Auckland UniServices have also been 
successful in generating research revenue from outside the government sector. 
Nonetheless it must be recognised that New Zealand’s total expenditure on 
biotechnology research is very small by global standards.  
 
Few innovations or processes in modern biotechnology have reached the stage of 
being commercialised. Genesis Research and Development is perhaps one of the 
closest to achieving income from a new biotechnology product; it initiated 
additional US phase II clinical trials of its PVAC Psoriasis treatment in June  
2002; one of over 300 biotech products now in phase II or phase III trials2 (Ernst 
& Young, 1999b, p. 35). 
 
Over the last few years there has been an explosion of interest in biotechnology in 
New Zealand. Politicians and policy makers have become increasingly interested 
in the role that biotech might play in the ‘new economy’; and aware of the policy 
initiatives in support of biotech which have been implemented by many of our 
competitors. The biotech industry has begun to achieve critical mass and has been 
increasingly effective in lobbying for policy changes that would make New 
Zealand more supportive of biotech R&D and innovation. At the same time, 
increasing levels of popular concern over the safety of some modern 
biotechnologies culminated in the setting up of the Royal Commission on Genetic 
Modification that spent over $6 million and 14 months listening to all sides of the 
debate. In October 2001 the government announced its response to the Royal 
Commission report, including permission for field trials to restart and a two-year 
ban on commercial release of genetically modified products3.  
                                                 
2 Clinical trials in the United States are conducted in phases. In Phase II trials, the study drug or 
treatment is given to a group of 100-300 people to see if it is effective and to further evaluate its 
safety. In Phase III trials, the study drug or treatment is given to large groups of people (1,000-
3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, 
and collect information that will allow the drug or treatment to be used safely. Source 
http://clinicaltrials.gov/ct/ 
3 This was lifted, amidst much vocal opposition and lobbying, in October 2003. 
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In early 2002 the Government released its Growth and Innovation Framework 
(GIF), which aims to return New Zealand to the top half of the OECD in terms of 
GDP per capita.  The GIF identified three potential growth areas that were worthy 
of special attention and government effort. These were information and 
communications technology, creative industries and biotechnology. Task forces 
were established in all three areas to agree priorities and develop action plans to 
stimulate growth and develop international competitiveness. The Biotechnology 
Task Force report was published in May 2003 and focuses on “three essential 
areas”: 
a)  the need to build critical mass; 
b)  the introduction of a package of regulatory reform to create a 
competitive environment for growth; and 
c)  the establishment of a robust international network through which to 
stimulate the flow of international investment” (Biotechnology 
Taskforce, 2003, p. 3). 
In the same month, the government published the New Zealand Biotechnology 
Strategy. The strategy aims to promote growth in biotechnology and draws on the 
work of the biotechnology taskforce. The strategy document includes the vision 
statement that: 
New Zealand responsibly develops and applies our world-class biological 
knowledge, skills, innovation and technologies to benefit the wealth, 
health and environment of New Zealanders, now and in the future 
(Ministry of Research Science and Technology, 2003, p. 3). 
It goes on to define three goals that support the Government vision for 
biotechnology: 
1. Build understanding about biotechnology and constructive 
engagement between people in the community and the biotechnology 
sector. 
2. Grow New Zealand’s biotechnology sector to enhance economic and 
community benefits. 
3. Manage the development and introduction of new biotechnologies 
with a regulatory system that provides robust safeguards and allows 
innovation. 
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2 Data Sources and Sector Size 
Research into the potential impact of modern biotechnology on New Zealand 
dates back to a 1983 discussion paper published by the Department of Scientific 
and Industrial Research (DSIR). The authors aimed to assess the significance for 
New Zealand industry of new developments in biotechnology and also made 
suggestions “on aspects of research and development which require emphasis if 
the perceived industrial opportunities are to be realised” (Hunt et al., 1983). This 
was followed in 1988 by a Department of Trade and Industry (DTI) study that 
aimed “to identify the impediments affecting the growth and development of 
biotechnology in New Zealand and to recommend any action the Government 
and/or department could take to overcome these impediments” (this has many 
parallels with the task assigned to the Biotechnology Task Force in 2003). DSIR 
and DTI did not attempt to quantify biotech activity in New Zealand but did 
identify 40-50 separate organisations working in the biotech sector.  
 
Kennedy and Davis (1994) assessed the impact of biotechnology on New Zealand 
industry over the period 1984-94 identifying around 504 separate organisations 
that were making direct use of biotechnology. They did not attempt an “all 
inclusive review of New Zealand Biotechnology because of the difficulties with 
the definition of the term biotechnology, and the difficulty in obtaining 
commercial and confidential information” (Kennedy & Davies, 1994, p. 2).  
2.1 Estimates by Tradenz 
An early attempt to put a monetary value on New Zealand biotech activity was 
conducted by Tradenz, based on a series of interviews with representatives from 
“companies, universities, research and development organisations and 
professional advisors” (Tradenz, 1994, p. 44). The authors classified the biotech 
industry into three groups using a broad definition of biotechnology and made 
estimates of turnover and foreign exchange revenue in each group, see Table 1. 
                                                 
4 The precise number varies depending on definition of a separate organisation, and approach 
taken to subsequent mergers and other organisational changes. 
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Table 1 Tradenz Estimates of Biotech Turnover and Foreign Exchange 
Earnings in 1994 
Group Description Members Turnover 
$ million 
Forex 
$ million 
1 Companies and 
organisations of a 
research and 
development nature 
which are primarily 
concerned with the 
creation of intellectual 
property in the medical 
and veterinary field, and 
to a limited extent its 
commercialisation 
 
Universities,  
Crown research 
institutes  
Technology 
development 
companies 
100 10 
2 Companies processing 
and marketing 
biologically active 
products - mainly meat, 
dairy and marine 
 
Processing and 
marketing 
Companies 
(includes 
nutraceuticals) 
150 120 
3 Companies 
manufacturing and 
marketing generic 
pharmaceuticals 
 
Pharmaceutical 
Companies 
80 7 
All Groups 330 137 
Source: Tradenz (1994, p. 44) 
 
Tradenz concluded that total turnover was around NZ$330 million with foreign 
exchange receipts of around NZ$137 million (around 0.7% of total merchandise 
exports). Industry estimates of growth rates for different categories of firm ranged 
from 16 to 25% per annum. These figures exclude traditional areas such as dairy 
and other food production e.g. New Zealand Dairy Exports of NZ$4.6 billion in 
1998/9. By including biotechnology in traditional food applications (Cheese, 
yoghurt, beer) and natural health products including deer velvet, BIOTENZ 
(1998) predicted that the industry could have a turnover of NZ$7-11 billion in 
2010. 
2.2 The 1998/99 Biotechnology Survey 
The most comprehensive attempt to quantify biotech activity in New Zealand was 
commissioned by the Ministry of Research Science and Technology (MORST) in 
1999. The main purpose was to “produce statistics concerning the present position 
of this industry in New Zealand” in order to “take stock of the current situation for 
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planning purposes”(Statistics New Zealand, 2000, p. 1). The survey was intended 
to focus only on modern biotechnology since it was thought that “the contribution 
to future economic development resulting from modern biotechnology is likely to 
be much greater than the potential contribution by its traditional counterpart”. The 
objectives5 of the survey were: 
i. To understand the present status, the structure and the future progression of 
the biotechnology industry in New Zealand 
ii. To assess the present status of strategic alliances, the links with the public / 
private research system and the potential for cluster development for the 
biotechnology industry 
iii. To provide a baseline on the utilisation of resources including the 
knowledge in the biotechnology industry against which progress could be 
compared at a future date  
iv. To identify the enabling factors and constraints facing the biotechnology 
industry in New Zealand 
 
The 1998/99 survey of modern biotechnology activity in New Zealand was 
conducted by Statistics New Zealand in 2000 with the results being published in 
April 20016. Questionnaires were sent out to 426 enterprises that had been 
identified as possible users of modern biotechnology processes. The survey 
achieved a 98% response rate with 180 enterprises being identified as users of at 
least one biotechnology process. The high response rate and wide ranging 
processes used to identify possible users of modern biotechnology suggest that the 
survey is likely to have captured almost all significant users of modern biotech in 
New Zealand over the survey period (1998/99). 
 
The survey also included enterprises that use traditional biotech processes (TBU). 
Estimates on the size of the traditional biotech ‘sector’ cannot be regarded as 
being complete since a significant numbers of other users of such processes were 
not included in the survey, or reported that they did not use modern biotech and so 
                                                 
5 Source: Ministry of Research, Science and Technology (2000) Draft Objectives for the 
Biotechnology Survey. 
6 Statistics New Zealand. (2001). Modern Biotechnology Activity in New Zealand. Wellington. 
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did not fill in the questionnaire. For example 33 ‘local authority’ enterprises 
reported use of biotech processes – primarily for treatment of sewage and 
wastewater but around 20 reported no involvement.  
 
Marsh (2001a) extensively re-analysed the SNZ dataset7. He reported that around 
80 biotech respondents conducted R&D; 57 of these conducted R&D into modern 
processes. Marsh also applied the Statistics Canada definition of a biotech 
enterprise to the SNZ data set ((Marsh, 2001a, p. 26). Based on this definition, the 
New Zealand biotech sector consisted in 1998/99 of 39 biotech enterprises with 
income from biotech of $205 million.  
 
2.3 The 2002 Biotechnology Survey 
In 2002 Marsh (2002) designed and implemented a survey of all enterprises in 
New Zealand that used modern biotech processes and/or all enterprises that 
conducted R&D using biotech processes (modern or traditional). Data from this 
survey are used in this paper to describe biotechnology in New Zealand and were 
also used to test a series of key hypotheses about the determinants of innovation.  
 
The 2002 survey was conducted by the author, in order to address research 
questions not covered in the 1998/99 biotech survey. The questionnaire was 
designed and drafted based on an iterative process involving consideration of: 
i. the data that should ideally be used to test the hypotheses; 
ii. the data or indicators that have been used in previous studies; 
iii. the outcome of those studies; and 
iv. the data or indicators that New Zealand respondents were likely to be 
willing and able to provide. 
 
International experience in the practice of surveys of innovation and 
biotechnology was reviewed; particularly Community Innovation Surveys 
conducted in the EU e.g. (Muzart, 1998) etc, OECD innovation surveys (OECD, 
                                                 
7 Some of his results presented here may appear to conflict with those published by Statistics New 
Zealand. This is mainly explained by different treatment of multiple responses from single 
enterprises. 
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2002), OECD studies of biotechnology e.g. (van Beuzekom, 2001) and Statistics 
Canada biotechnology surveys e.g. (McNiven, 2001a; Pattinson, Van Beuzekom, 
& Wyckoff, 2001). An extended email discussion was also held with staff at 
Statistics Canada; the first national statistical organisation to implement a 
comprehensive biotechnology survey. 
  
Survey design took account of New Zealand experience with studies of innovation 
and biotechnology; most notably lessons learned in the conduct and analysis of 
the 1998/99 survey of modern biotechnology; see (Marsh, 2001b), R&D 
expenditure surveys e.g. (Ministry of Research Science and Technology, 2002) 
and business practices surveys; see (Statistics New Zealand, 2002). Survey design 
was also discussed with government (MoRST and SNZ) and representatives of the 
biotechnology industry. A detailed research proposal was written up and 
circulated for comment. Ethical approval was secured from the Waikato 
Management School ethics committee. 
 
The study population was defined as ‘all enterprises using modern biotech 
processes and/or all enterprises conducting R&D using biotech processes (modern 
or traditional)’. Inclusion of enterprises that conduct R&D using modern and 
traditional processes allowed investigation into the differences between these 
organisations. Enterprises that use traditional processes only and do not carry out 
R&D were excluded for both practical and theoretical reasons. In practice, they 
are not well suited to a study of innovation as they tend to exhibit low innovation 
rates and an unwillingness to participate in voluntary innovation surveys. From a 
theoretical perspective these enterprises are of less interest since the hypotheses 
tested focus on factors affecting innovative output and innovation rate – rather 
than why enterprises are, or are not innovative. It should also be noted that these 
enterprises would not normally be regarded as being part of the biotech ‘sector’. 
 
Enterprises contacted were identified from a database of all biotech enterprises in 
New Zealand built up over three-year period 1999-2002. Entries in the data base 
are based on data from a variety of sources including: 
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i. the NZBA web directory; 
ii. firms and organisations attending NZBA conferences; 
iii. the BIOTENZ website; 
iv. A’Courts and other commercial directories; 
v. internet searches; 
vi. print media articles (internet searches based on key words such as biotech, 
gene etc); 
vii. the website of the Royal Commission on Genetic Modification; 
viii. the FRST website; and 
ix. published sources e.g. Kennedy & Davies (1994) and Packer, Robertson, & 
Wansbrough (1998). 
 
A total of 146 questionnaires were sent out in April 2002. Responses were 
received from 93 enterprises indicating a ‘crude’ response rate of 64%. The 
sample frame was adjusted to 138 enterprise units by subtracting enterprises that 
reported that they were not involved in biotech. Sixty one usable responses were 
received indicating a ‘usable’ response rate of 44%.  
2.4 Overview of Sector Size Estimates  
Recent attempts to quantify New Zealand biotech activity are summarised in 
Table 2. It may be seen that different interpretations of the terms biotechnology 
and biotechnology sector continue to hinder attempts to measure biotech activity 
in a way that is comparable over time and across nations. 
 
Ernst and Young publish annual reports on the state of the biotech industry in 
various countries (Ernst & Young, 1999a, 1999b); in their survey of the 
Australian industry they identified 120 core biotechnology companies. They 
excluded not-for-profit enterprises and traditional biotechnology operations and 
defined ‘core biotechnology’ companies as “those whose business is entirely or 
substantially biotechnology related and that have a significant commitment to 
technological innovation”. Based on this definition there were around 30 core 
biotech enterprises in New Zealand in 1998/99. 
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Estimates of the size of the New Zealand biotech sector range from 30 core 
biotech companies with annual income of the order of $200 million, to the 
Biotechnology Taskforce (350 organisations in the ‘biotech community’) to 
BIOTENZ income estimates of several billion dollars (including traditional food 
applications such as cheese, yoghurt and beer).  
 
These alternative estimates serve different purposes and are not mutually 
exclusive. Authors aiming to take a comprehensive approach that promotes all 
New Zealand organisations that use biotech tend to include both traditional and 
modern applications. On the other hand international statistics and the economic 
literature since the mid 1980s has generally concentrated on modern 
biotechnology and the biotech sector is often taken internationally to refer to the 
population of ‘core’ private sector enterprises that conduct R&D into modern 
biotechnology.  
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Table 2 Size of the New Zealand Biotech Sector 
Source Year No. of 
Enter-
prises 
No. of 
Empl-
oyees 
Biotech 
Income $ 
million 
Remarks 
BIOTENZ 
Capability 
Survey 
(Cooper, 2003) 
2003 258 
42 core 
4000  Comprehensive survey of the 
biotech community including 
core biotech firms, natural 
products and suppliers. 
Biotechnology 
Taskforce 
(2003) 
2003 350 
40 core 
3900  350 organisations in the 
“biotech community” includes 
natural product manufacturers, 
importers, lawyers, consultants, 
equipment suppliers, 
government agencies etc 
Hopper and 
Thorburn 
(2003) 
2002 60 core 
70-80 
other 
1200  60 “dedicated, core biotech 
firms …70-80 involved in 
biotech in a more minor way” 
Statistics New 
Zealand (2001) 
1998 
/99 
180 27278 475 Includes most enterprises that 
use modern biotech and some 
that use traditional biotech 
processes 
Marsh (2001a) 1998 
/99 
57 16679 236 Includes only enterprises that 
use modern processes and 
conduct R&D 
Marsh (2001a) 1998 
/99 
39 170810 205 Based on Statistics Canada 
definition of a biotech 
enterprise11 
Marsh (2001a) 1998 
/99 
27   No. of Dedicated Biotech 
Enterprises (DBF)12 
Kennedy 
(1994) 
1993 5013   Broad definition of biotech 
Tradenz (1994) 1994   330 
turnover 
Broad definition of biotech 
Source: various sources collated by the author 
 
Marsh (2001a) divided users of biotech processes into four categories (see Figure 
1) based on whether they used modern or traditional processes and whether they 
were creators (engaged in R&D) or simply users of biotechnology processes. The 
                                                 
8 Head count of employees associated with biotechnology 
9 Full-time equivalents (year to 30 June ’99) 
10 Head count 
11 conduct R&D, have a minimum of five biotech employees and biotech expenditure of at least 
NZ$150,000 
12 DBFs defined as enterprises that received 100% of their income from biotech. A further nine 
received 75-100% of their income from biotech. 
13 The precise number varies depending on definition of a separate organisation, and approach 
taken to subsequent mergers and other organisational changes. 
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 Modern   !!!!! Traditional 
Modern Biotech 
Enterprises  
(MBEs) 
Traditional Biotech 
Enterprises 
(TBEs) 
Creators 
 
 
 
 
Users 
Modern Biotech 
 Users 
(MBUs) 
Traditional Biotech 
Users 
(TBUs) 
 
term Modern Biotech Enterprise (MBE) is used to describe respondents that are 
engaged in R&D into at least one modern biotech process.  
 
 
 
 
 
Source: Marsh (2003) 
 
Based on this definition, New Zealand’s modern biotech ‘sector’ consisted in 
1998/99 of approximately 57 enterprises (15 primary product and manufacturing 
firms, 24 research organisations and 6 universities) employing around 1700 
people. Enterprises were split fairly evenly between the private sector (30) and the 
public sector (27). They reported expenditure on biotech of NZ$202 million and 
income from biotech of NZ$236 million. This compares to enterprise income 
from all sources of NZ$2.1 billion, i.e. biotech provided around 11% of income 
for the 57 enterprises. Twelve enterprises reported that they received all of their 
income from biotech and so might be referred to as dedicated biotech firms. A 
selection of key indicators of biotech activity based on analysis in Marsh (2001a) 
is provided as Table 3. 
Figure 1 Classification of Biotech Respondents 
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Table 3 Key Indicators of Biotech Activity in New Zealand 1998/99 
 
 
Source: Marsh (2001a). 
Note: c indicates cell ‘confidentialised’ to give effect to the confidentiality provisions of the 
Statistics Act 1975.  
 
A further 36 enterprises used modern biotech processes (but were not engaged in 
R&D) and employed around 950 people in ‘biotech based activities’, which 
provided income of NZ$112 million. Twenty four enterprises, employing around 
220 people conducted R&D using traditional biotech processes but were not 
involved in modern biotechnology.  
 Modern 
Biotech 
Enterprises 
Traditional 
Biotech 
Enterprises 
Modern 
Biotech 
Users 
Traditional 
Biotech Users 
All  
Biotech 
Respondents 
No. of Respondents and Processes      
No. of Respondents 57 24 36 63 180 
No. in Private Sector 30 21 21 30 102 
Biotech Processes per enterprise 19 3 8 4 9 
No. Involved in DNA Based Processes 42 0 9 0 51 
Innovation Indicators      
No. New Products last 3 yrs 114 18 27 18 180 
No. New Processes last 3 yrs 105 21 45 9 177 
New Products & Processes per Enterprise 3.8 1.8 2.0 0.4 2.0 
No. Processes New to the World last 3 yrs 30 6 3 0 39 
No. New Products Planned Next 3 years 207 24 42 21 298 
No. New Processes Planned Next 3 years 219 12 24 30 288 
New Products & Processes per Enterprise 7.5 1.5 1.8 0.8 3.3 
No. of Patents Applications Last 5 Yrs 147 6 3 0 156 
Patents Applications per Enterprise 2.6 0.3 0.1 0 0.9 
Biotech Income and Exports      
Total Income ($ million) 2,124 1,008 1,647 2,475 7,254 
Biotech Income ($ million) 236 68 112 59 475 
Biotech as % of Total Income 11% 7% 7% 2% 7% 
Biotech Income per Enterprise ($ million) 4.1 2.8 3.1 0.9 2.6 
Biotech Exports ($ million) 60 c1 40 c 170 
Biotech Employment      
Full-time Equivalents (yr to 30 June ‘99) 1,667 218 944 155 2,984 
PhDs 667 c c c 703 
Graduates 1,512    1,824 
Graduates per Enterprise 27    10 
Biotech Alliances      
% Reporting Biotech Alliances 90% 50% 42% 24% 53% 
% Reporting Alliance with CRI 68% 25% 17% 14% 32% 
% Reporting Alliance with Business 47% 13% 17% 10% 22% 
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2.5 International Comparisons 
The OECD has taken the lead in attempting to develop internationally comparable 
statistics on biotechnology. It held the first ad hoc meeting on Biotechnology 
Statistics in March 2000 and decided to address the lack of biotechnology 
statistics in OECD member and observer countries by preparing a compendium of 
biotechnology statistics (van Beuzekom, 2001). The compendium provides an 
invaluable source of information on biotech in the OECD, although the variety of 
definitions and data collection methods make the production of reliable 
comparisons pretty well impossible. Selected data from Van Beuzekom and a 
recent update by Devlin (2003) are summarised in Table 4.  
Table 4 Biotechnology in Numbers 
 Data 
Year 
Total 
Number of 
Companies 
Involved in 
Biotech 
Number  
of ‘Core’1 
Biotech 
Companies 
Total  
Number  
of Biotech 
Employees 
‘Core’ 
Biotech 
Companies 
per million 
inhabitants, 
20007 
Australia ‘99   120  3801  
Belgium ‘97  52   4471 5.3 
Canada ‘99   358  7695 12.2 
Denmark ‘98   74  34116 9.6 
Europe ‘99   1351  53511  
Finland ‘99   110  8200 10.4 
France ‘99   380  110002 5.8 
Germany ‘99  709  279  2288453 5.9 
Ireland ‘99  140  50  11.2 
Israel ‘99   135  3800  
Italy ‘99   45  1.1 
Japan ‘99  1000  394  293584  
Netherlands ‘99  300  55  5.0 
Norway ‘00   44  10154 8.3 
New Zealand5 ‘00 250-350  40  2727 10.4 
Spain ‘99  200  22  90000 0.8 
Sweden ‘99   144  2998 26.0 
Switzerland ‘99  233  117  7000 12.6 
UK ‘99   275  137806 7.6 
USA ‘99   1273  162000  
Source: van Beuzekom (2001, p. 42) and Devlin (2003, p. 11) 
Notes: 1. ‘Core’ biotech firms have their main activities in biotechnology although 
they can be active in other fields. 2. Only covers 255 companies. 3. Covers all 709 
companies. 4. Only covers 210 companies. 5. Data inserted based on Table 2.  
6. Based on 221 companies and 1997 data. 7. Data from Devlin (2003, p. 11) 
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The 2001 edition of OECD’s STI Scoreboard (2001) included data on public 
funding of biotechnology R&D and patents, for the first time, see Table 5. Data 
for New Zealand have been inserted based on Rolleston  (1999, p. 46) who 
reported that the government spent an estimated NZ$100m a year14 on 
biotechnology-related research ranging from genomics to processing of natural 
products and Wright, (2000, p. 7) who reported that around NZ$18 million is 
spent on research involving genetic modification (Wright, 2000, p.7). 
  
1997 
Biotechnology 
R&D, 1997 
$ million PPP 
1997 
GBAORD1 
$ million 
PPP 
1997 
Biotech 
R&D as % 
of 
GBAORD 
20002 
Biotech 
R&D as % 
of 
GBAORD 
Australia (‘98) 196.3 2533 7.8 8.0 
Austria 16.8 1147 1.5  
Belgium 181.7 1314 13.8  
Canada 261.4 2581 10.1 10.6 
Czech Republic (’99) 7.8 749 1.0  
Denmark 45.2 946 4.8 10.4 
Finland 94.5 1165 8.1 9.0 
France 560.0 12683 4.4  
Germany 1048.2 15596 6.7 3.1 
Greece 6.5 431 1.5 8.3 
Iceland 0.9 69 1.3  
Ireland 15.0 230 6.5 0.6 
Italy 32.1 7330 0.4 0.7 
Netherlands 78.0 3070 2.5  
New Zealand3 12.3–68.0 400 3-17 14.6 
Norway4 26.8-32.2 880 3-3.7 3.7 
Portugal 19.2 782 2.5  
Spain 15.5 3203 0.5 3.2 
Sweden5 65.6 1795 3.7  
Switzerland5 16.4 1380 1.2  
United Kingdom 705.1 9056 7.8 2.6 
Notes: Sources (OECD, 2001, 2003) and authors estimates. 
1. GBAORD; Total Government Budget Appropriations or Outlays for R&D. 
2. 2000 or nearest year available, Eurostat National Sources May 2003. 
3. Author’s estimates based on published data. 
4. National estimates. 
5. GBAORD has been estimated. 
                                                 
14 Consistent with estimated spending of  $127 million in 2002/3, (Ogilvie, 2003). 
Table 5 Government Funded Biotechnology R&D 1997& 2000 
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Based on Wright’s narrower definition, New Zealand is spending around 3% of 
GBAORD15 on biotech R&D – giving it a middle ranking amongst the OECD 
members reported above. Probably a rather wider definition should be adopted 
suggesting that New Zealand’s proportional effort on biotech R&D is comparable 
with the leaders e.g. Canada, Australia Belgium, UK. This approach was taken by 
the OECD (2003) which reported that New Zealand put the highest proportional 
effort into biotech R&D16. Not surprisingly, a rather different picture emerges in 
absolute terms with New Zealand’s total biotech GBAORD being the third 
smallest of the 21 countries listed. 
 
Some more accurate international comparisons can be made based on data from 
the Statistics New Zealand biotech survey, since this was closely modelled on 
surveys carried out by Statistics Canada. However there are some important 
differences; the New Zealand definition of biotech included several additional 
processes and so was somewhat wider than that used in Canada; the number of 
biotech firms is also not directly comparable since the Canadian survey excluded 
firms that had less than five employees and less than C$100,000 R&D 
expenditure.  
 
An approximate comparison between the two data sets is included as Table 6. It is 
based on application of the Statistics Canada definition of a biotech enterprise to 
the New Zealand data set; namely enterprises which conduct R&D, have a 
                                                 
15 Government Budget Appropriations or Outlays on R&D 
16 Major differences in biotech R&D as a percentage of GBAORD between 1997 and 2000 (see 
Table 5) are probably caused by changes in definition. R&D definitions for the 2000 data vary 
across countries, especially with respect to inclusion or exclusion of biotechnology R&D 
performed by the higher education sector. The data are based on: government budget 
appropriations or outlays for R&D (GBAORD) for Australia, Canada, Germany, Greece, Ireland, 
Italy, Korea, Spain and the United Kingdom; government-financed gross domestic expenditure on 
R&D (GERD) for Norway; and the sum of R&D performed by the government, higher education 
and private non-profit sectors for Denmark, Finland and New Zealand (OECD, 2003). 
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minimum of five employees and biotech expenditure of at least NZ$150,000. Data 
for Australia are also included although based on a narrower definition. 
Table 6 Comparison of Biotech in New Zealand, Canada and Australia 
 Canada  
1999 
Australia 
1998/99 
NZ 
1998/99 
Population (1997) 30.3 18.5 3.8 
No. of biotech enterprises 358 120 39 
Total biotech revenue (NZ$ m) 2850 1077 205 
Biotech revenue per million population (NZ$ m) 94 58 54 
Revenue per firm (NZ$ m) 8.0 9.0 5.3 
Biotech related employees (Headcount) 7695 3801 1708 
Biotech related employees per million population 254 205 449 
% of products and processes in R&D stage 49% 47% 72% 
Sources: NZ - Marsh (2003), Canada - McNiven (2001a), Australia - Ernst & Young 
(1999a). 
 
New Zealand’s biotech revenue per million population (NZ$54 million) is rather 
lower than Canada's (NZ$94 million), but the difference is fairly small 
considering Canada’s higher per capita income and proximity to the United States. 
New Zealand has a rather lower mean revenue per biotech firm (NZ$5.3m vs. 
NZ$8.0m); consistent with the predominance of small firms in the New Zealand 
economy. New Zealand appears to have a significantly higher rate of biotech 
employment. There is some evidence that use of biotech processes in New 
Zealand is at an earlier stage with 72% being at the R&D stage against 49% in 
Canada. 
 
3 Enterprise Types in the NZ Biotech Sector 
3.1 Classification by Industry Group 
Users of modern and traditional biotech processes are spread fairly evenly over 
five main industrial groups: food and non-food manufacturers, scientific research, 
and local government and health services. The proportion of New Zealand 
enterprises that make use of biotech is very low; fewer than half of one per cent of 
enterprises in the above industrial groupings. Most modern biotech R&D is 
conducted within research organisations, universities and a small number of 
private companies. Table 7 summarises data from Statistics New Zealand (2001) 
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and Marsh (2001a; 2002) on the number of enterprises involved in biotech, by 
industrial group. 
 
Biotech respondents were concentrated in a small number of industrial groups; 
120 of the SNZ’s 180 respondents falling under 8 ANZSIC categories (at the 5 
digit level), see Table 8. 
 
Around 60% of SNZ’s biotech respondents were from the private sector 
(including manufacturers, research enterprises and laboratories), the remainder 
being mainly comprised of local and regional authorities, universities, crown 
research institutes and health providers17.  The smaller number of enterprises 
responding to the 2000/01 survey reflects a change in the survey population and a 
lower response rate – not a fall in the number of enterprises. 
Table 7 No. of Enterprises Responding to Biotech Surveys, by 
Industrial Grouping, 1998/9 and 2002 
Industrial Group No.  
Enterprises 
Involved in  
Biotech 
Activity 
1998/99 
No. Modern 
Biotech 
Enterprises 
1998/99 
No. MBE 
Respondents 
2001/02 
No. All 
Enterprises 
in each 
Industrial 
Group 
1998/99 
Primary Products 6 3 5 8,122 
Food 
Manufacturing  
33 3 4 1,268 
Non-Food 
Manufacturing 
24 9 8 591 
Scientific Research  36 24 10 5,404 
Local Government 
Administration  
33 6 Not sampled 201 
Tertiary Education 9 6 6 76 
Health Services  24 3,536 
Other  12 
9 1 
25,036 
Total  180 57 34 44,234 
Note: Other includes water supply, sewerage and drainage services, veterinary 
services, parks and gardens.  
Sources: Statistics New Zealand (2001) and Marsh (2001a; 2002). 
                                                 
17 Formerly known as Crown Health Enterprises 
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Table 8 Number of Biotech Enterprises Responding to 
Biotech Surveys, by ANZSIC Category 
 1998/99 2000/01 
Dairy Product Manufacturing  
Wine Manufacturing  
Medicinal and Pharmaceutical Product 
Manufacturing Scientific Research  
Technical Services nec  
Local Government Administration  
Higher Education  
Hospitals (except psychiatric)    
Total No of Respondent in above categories  
6 
9 
15 
24 
6 
33 
12 
15 
120 
0 
0 
10 
13 
1 
0 
12 
1 
37 
Other ANZSIC Categories 60 24 
Sources: Marsh (2001a; 2002). 
 
 
3.2 Classification by Product End-Use 
Modern biotechnology is used in a number of different economic sectors ranging 
from food and non-food manufacturing through various primary industries to 
health, diagnostic and environmental applications, see Table 9.  
 
Table 9 Classification by End-Use Sector 
Hopper and Thorburn 
200218 
 
End-Use Sector SNZ 1998/99 
All 
Respondents 
SNZ 
1998/99 
MBEs 
NZ Australia 
Human Health 30% 53% 29% 40% 
Food Processing 33% 42% 10% 2% 
Mining/Energy etc 4% 5% 
Environment 35% 37% 8% 11% 
Agbiotech 32% 63% 
Forest Products 8% 21% 
Aquaculture 13% 37% 
25% 19% 
Genomics 12% 42% 
Custom Synthesis 8% 21% 
Other 13% 21% 
13% 
including 
diagnostics 
22% 
including 
diagnostics 
Multiple Sector na na 13% 4% 
Sources: Marsh (2001a), Hopper & Thorburn (2003). 
 
 
Modern Biotech Enterprises reported that they were researching and developing 
products, processes and services for use in the ag-bio and human health sectors, 
                                                 
18 Data adjusted by removing  biotech suppliers. 
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followed by food processing, genomics/molecular modelling, aquaculture and the 
environment. Food manufacturers were generally classified as MBEs because of 
their use of non-DNA based processes e.g. peptide sequencing, immune 
stimulants, antigens and antibodies etc.  
 
Other biotech categories exhibit a similar pattern while being influenced by the 
industry group of some respondents; so for example the environment industry 
sector was reported most frequently by Traditional Biotech Users,  reflecting  the 
waste treatment activities of  local authorities, while Modern Biotech Users most 
reported sector was human health – reflecting the activities of health services 
respondents. 
 
A similar pattern emerges when ‘end use sector’ is tabulated against industry 
group see Marsh (2001a, p. 34). The main end use sector is in many cases ‘self 
defined’: 
x. Food manufacturers reported food processing as the main end use sector; 
xi. Non-food manufacturers were mainly involved in ag-bio, human health 
and food processing ; 
xii. Scientific research organisations were involved in most sectors, ag-bio 
being the most common; 
xiii. Local government was mainly involved in environmental processes (water 
and waste treatment) 
xiv. The university and polytechnic group were involved in all areas; human 
health being the most common; 
xv. Health services organisations were all involved in human health and have 
some involvement in ag-bio and the environment. 
 
Classification according to end-use may allow better international comparisons 
but has the disadvantage that many enterprises are involved in multiple sectors. 
This may explain the lack of correspondence between the end-use sectors reported 
by Hopper and Thorburn (2003), in which most enterprises were assigned a single 
end-use sector, and Marsh (2001a) where each enterprise can select several 
sectors.  
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3.3 Year of Formation and First Biotech Activity 
Enterprises responding to the 2001/02 survey were formed as early as 1840, 
although 35% had been formed since 1990. Biotech activity was reported to have 
started as early as 1878 but in most cases had started much more recently; 49% 
had started since 1990 and 85% since 1970, see Figure 2. 
 
 
Source: Marsh (2002). 
 
3.4 Biotech Processes Used 
Biotech enterprises in New Zealand may also be described by reference to the 
types of biotech process that they use and whether these processes are used for 
R&D or for production. Respondents to the 2002 survey were asked to review a 
list of 17 groups of biotech processes and indicate whether each process/group 
was currently used for R&D or for current production, see Figure 319.  
 
It may be seen that the most commonly used process group was ‘extraction, 
purification etc’ followed by ‘microbiology or virology etc’ and ‘gene probes or 
DNA markers’. The way in which process groups are used varies considerably, so 
for example bio-informatics and GE or DNA sequencing are used almost 
exclusively for R&D, while  ‘fermentation or bioprocessing’ is generally used for 
current production.  
 
                                                 
19 This Figure provides data on respondents to the 2002 survey of organisations conducting biotech 
R&D. For data on all biotech users see Marsh (2001a, p. 11). 
Figure 2  Year of Enterprise Formation and First Biotech Activity 
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Source: Marsh (2002). 
Note: ‘Currently Used’ denotes total number of users including those who use biotech 
processes for R&D and for ‘Current Production’. 
 
 
Figure 3 No. of Respondents Using Biotech Processes in R&D and for 
Current Production in 2002 
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Use of modern biotech in New Zealand is at an early stage of development with 
many enterprises being involved primarily in R&D. Overall 92% of biotech 
respondents (2002 Survey) used at least one biotech process for R&D or process 
development, see Table 10.  
 
66% reported use of biotech processes for current production. There is significant 
variation between the different biotech areas, for example: 
i. 90% of enterprises using DNA based processes conducted R&D in this 
area while only 30% used these processes for current production; 
ii. 87% of enterprises using biochemistry based processes conducted R&D in 
this area while 47% used these processes for current production; 
iii. Enterprises using bioprocessing based processes were most likely to use 
them for current production (63%). 
 
Table 10 Percentage of Enterprises Involved in Different Biotech Areas 
by Stage in 2002 
Biotech Area No. of 
Enterprises 
Involved at 
any stage 
% Using 
Processes 
in R&D 
2000/01 
% Using 
Processes 
in R&D 
1998/99 
% Using 
Processes 
for Current 
Production 
2000/01 
% Using 
Processes 
for Current 
Production
1998/99 
DNA Based Processes 30 90% 76% 30% 24% 
Biochemistry Based 45 87% 57% 47% 43% 
Bioprocessing Based 51 90% 37% 63% 37% 
Environmental Biotech 8 88% 54% 38% 19% 
Enterprises Involved in 
each Stage 61 92% 53% 66% 45% 
Note: Percentages are expressed as a proportion of the number of enterprises involved in 
each area e.g. ‘90% of the 30 enterprises that used DNA based processes used DNA 
based processes for R&D’. Enterprises may use the same process in more than one stage. 
Sources: Marsh (2001a; 2002). 
 
3.4.1 Number of Processes Used 
Figure 4 provides a pictorial representation of biotech process use in the different 
industrial groups. It illustrates the number of processes used  in different biotech 
areas.   Each black rectangle indicates use of one process group by one 
respondent. It can be seen that respondents in scientific research and higher 
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education use the most processes; including most in the DNA, biochemistry and 
bioprocessing based areas, while manufacturers mainly use bioprocessing based 
processes. Private sector organisations (primary, food and non-food industrial 
groups) were involved in fewer process categories – an average of 2.5 to 3.2 per 
respondent than public sector organisations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Marsh (2002) 
 
3.4.2 Age distribution of processes 
Data on the age distribution of biotech processes provides useful information on 
the development of the biotech industry over time and may also be compared with 
similar data from overseas. Average age in use in New Zealand is longer than in 
Figure 4 Process Use by Industrial Group 
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Canada for all but two process categories (see Figure 5), possibly because of the 
lower number of new entrants in New Zealand. 
  
There are distinct differences between modern and older biotechnology processes. 
Genomics exhibits a typical age structure for a recent process; 56% have used this 
process for 5 years or less, 83% have used it for 10 years or less. 
Extraction/purification/separation is typical of a more mature technology;  24% 
started using this process within the last 5 years (often these are new enterprises). 
A further 24% have been using this process for at least 20 years. See Figure 6 and 
Figure 7. 
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Source: Marsh (2002), McNiven (2001b, p. 11).  
Note: Data for New Zealand is drawn from the 2000/01 survey; adjusted for survey year.  
  
Figure 5 Number of Years Biotechnologies Used in Canada and New Zealand 
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Figure 6 Age Distributions for Selected Biotech Processes 
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Biochemistry/Immunochemistry based processes
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Figure 7 Age Distributions for Selected Biotech Processes 
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4 Enterprise Size 
4.1 Expenditure data 
4.1.1 Data from the 1998/99 Survey 
Respondents to the 1998/99 survey estimated that income of $475 million was 
attributable to ‘biotechnology activity’, in the year ended June 1999 - $326 
million from private sector respondents, $149 million from the public sector. This 
compares to respondents’ income from all sources of $7.25 billion i.e. overall 
biotech provided around 7% of income for the 180 biotech using enterprises20.  
 
Various difficulties associated with the data on income and expenditure mean that 
these estimates should be treated with caution. Enterprises were asked to estimate 
the proportion of their total income and expenditure that could be attributed to 
biotechnology. Such an instruction is open to widely varying interpretations21, so 
for example dairy product manufacturers’ estimates varied between zero and 
100% of their income.  
 
Fifteen percent of enterprises which use biotech processes reported that they 
received no income attributable to biotechnology. Seventy three percent received 
less than 50% of their income from biotech, while 15% attributed all of their 
income to biotech. Within the MBE group 53% received 0 > 25% of their income 
from biotech, while 15% (around 9 enterprises) received all of their income from 
biotech – such firms are commonly termed Dedicated Biotechnology Firms (DBF) 
in the international literature, see Table 11 below. 
                                                 
20 Expenditure of $405 million was attributable to biotech activity; 6% of total expenditure ($6312 
million). 
21 depending on interpretation of ‘attributable’ and whether the respondent concentrated only on 
modern biotech. Based on a broad interpretation it could be said that all dairy manufacturing 
income is attributable to biotech. Separation of the proportion of this attributable to modern 
biotech would be very difficult. These issues are also discussed in Statistics New Zealand (2001) 
and Marsh (2001b). 
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Table 11 Biotech Income as a Percentage of Total Income (1998/9) 
Percentage of Income 
from Biotech 
All 
Groups 
Modern 
Biotech 
Enterprises 
0 15% 5% 
0 > 25% 47% 53% 
25 > 75% 17% 16% 
75 > 100% 5% 11% 
100% 15% 16% 
Source: Marsh (2001a, p. 22)  
 
4.1.2 Data from the 2001/02 Survey 
The 2001/02 survey, conducted by the author (Marsh, 2002), was addressed to 
organisations thought to be conducting R&D using modern or traditional biotech 
processes; a different survey population to the 1998/99 survey. It provides data on 
some expenditure variables not included in the 1998/99 survey e.g. R&D 
expenditure, biotech R&D expenditure and revenue from new biotech 
products/processes. Estimates in Table 12 and Table 13 have been obtained by 
adjusting category totals based on the response rate in each category22. These 
estimates are subject to wide confidence limits and so should be used with 
caution. 
                                                 
22 For example response rate in the non-food manufacturer’s category was 67%. Total R&D 
expenditure for all respondents was $9.7 million. Estimated R&D expenditure for all non-food 
manufacturers (that conduct biotech R&D) is $9.7m/0.67=$14.47m 
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Table 12 Expenditure and Revenue Estimates 2001/2 ($ millions) 
Industrial Group Expenditure 
2000/01 
Revenue/ 
Sales 2000/01
R&D 
Expenditure 
2000/01 
% 
Expenditure 
on R&D 
Primary Products 27 33 3 13% 
Food Manufacturing 4,566 5,384 70 2% 
Non-Food Manufacturing 103 179 14 14% 
Scientific Research 668 553 478 72% 
Tertiary Education 101 61 45 45% 
Health Services & Other 619 623 3 1% 
Total 6,085 6,833 616 10% 
Source: Marsh (2002) 
Note: These are population estimates for all biotech enterprises conducting R&D. 
Estimates for scientific research and tertiary education are based on responses for sub-
units and so refer only to the parts of those organisations engaged in biotech research. 
 
 
Respondents indicated that R&D constituted around 10% of total expenditure; the 
proportion varying from a high of 72% in the scientific research group to a low of 
1-2% for food-manufacturers, health services and other. Respondents spend far 
more on R&D than the industry average; the dairy industry is reported to spend 
around 1% of turnover on R&D23, while R&D expenditure as a proportion of 
value added of manufactured products was 1.3 percent in 1999/2000 (Ministry of 
Research Science and Technology, 2002, p. 17).  
Table 13 Biotech R&D Expenditure Estimates 2001/2 
Industrial Group Biotech 
Expenditure 
2000/01 
Biotech 
Expenditure 
as % of Total 
Expenditure
Biotech R&D 
expenditure 
2000/01 
Biotech ‘New 
Revenue’24 
Primary Products 4 16% 2 12 
Food Manufacturing 20 0% 14 56 
Non-Food Manufacturing 69 67% 13 13 
Scientific Research 268 40% 266 8 
Tertiary Education 20 20% 16 0 
Health Services & Other 9 1% 3 1 
Total 390 6% 313 91 
Source: Marsh (2002) 
Note: These are population estimates for all biotech enterprises conducting R&D. 
 
                                                 
23 The dairy industry (dominated by Fonterra) is reported to spend “in excess of 1% of it’s annual 
turnover on R&D; in excess of $100million per year” Marshall (2001). 
24 From biotech products/processes introduced in the last 3 years 
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Biotech expenditure in 2000/01 was estimated to be around $390 million; this can 
be compared with an estimate of $260 million for 1998/9925. These estimates are 
consistent with the sector growth rate of around 20% per annum reported by some 
industry observers26 (Ernst & Young, 2003). Expenditure on biotech R&D ($313 
million) comprised around 80% of all biotech expenditures. 
4.2 Human Resources data 
Respondents to the 1998/9 survey were asked to provide data on their employees 
‘supporting biotech activity’. They were specifically asked not to include staff 
performing indirect support to biotech activities e.g. central finance or personnel 
or other similar centralised support services.  
 
 
 
 
 
 
 
 
 
Source: Marsh (2002) 
 
Survey respondents reported that a total of 3057 (or 2984 full time equivalent) 
staff supported biotech activity. Around 67% were graduates and 26% had PhDs. 
The largest employee group came from the health services industrial group, 
followed by the tertiary education and research groups (see Figure 8). 
 
                                                 
25 Biotech expenditure by all respondents in MBE and TBE groups – Marsh (2001) Unpublished 
Results from Further Analysis of the 1998/99 Survey data. 
26 Growth from $260m in 1998/99 to $390m in 200/01 indicates a growth rate of 22.5% per 
annum. 
Figure 8 Number of Biotech Employees by Qualification and Industrial Group 
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Most graduates were employed by the tertiary education and research groups 
(most health services biotech employees are not graduates). The concentration of 
qualified staff is most marked for staff with PhDs – 88% of these were employed 
within these two groups. MBEs employed 1667 biotech staff (FTE) – 56% of the 
total for all respondents. Employment of qualified staff was heavily concentrated 
in MBEs; they employed 83% of biotech graduates and 95% of PhDs. 
 
The 20002 survey provides data on the number of employees engaged in biotech 
R&D; this variable was not included in the 1998/99 survey. Estimates in Table 14 
and Table 15 have been obtained by adjusting category totals based on the 
response rate in each category27. These estimates are subject to wide confidence 
limits and so should be used with caution. 
 
Table 14 No. of Employees (2002) 
Biotech Employees Industrial Group All 
Employees PhD MSc or 
MPhil 
BSc 
or 
BTech
Diploma 
or Cert 
Other 
Qual 
No 
Qual 
Total 
Biotech 
Staff 
Primary Products 624 27  24 68 14 11 97 241
Food Manufacturing 21,568 26  21 174 205 16 211 653
Non-Food Manufacturing 639 33  21 185 60 7 115 421
Scientific Research 5,022 527  129 517 85 22 32 1,298
Tertiary Education 1,502 243  107 227 21 20 14 632
Health Services & Other 11,863 37  7 26 2 2 - 74
Total 41,218 893  309 1,196 387 78 469 3,318
Source: Marsh (2002) 
Note: These are population estimates for all biotech enterprises conducting R&D 
 
The 2002 estimate of 3,318 biotech staff may be compared with a head count of 
2053 reported for June 199928. These estimates are also consistent with the high 
sector growth rate mentioned in above. 
                                                 
27 See footnote 22 for estimation method. 
28 Headcount at June 1999 for all respondents in MBE and TBE groups – Marsh (2001) 
Unpublished  Results from Further Analysis of the 1998/99 Survey data. 
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Table 15 No. of Employees Engaged in Biotech R&D 1999 and 2002 
Industrial Group 1999 2002 
Primary Products         95         116 
Food Manufacturing         42           68 
Non-Food Manufacturing         51           75 
Scientific Research       978      1,227 
Tertiary Education       463         527 
Health Services & Other         33           30 
Total    1,661      2,044 
Source: Marsh (2002).  
Note: These are population estimates for all 
biotech enterprises conducting R&D 
 
Respondents to the 2002 survey indicated that around 60% of all ‘biotech staff’ 
were engaged in R&D. The number of staff engaged in R&D increased from 
around 1660 in 1999 to 2044 in 2002,  indicating growth of around 7% per 
annum. 
 
5 Innovation Output 
5.1 Product and Process Development 
One indication of the rate of innovation by biotech respondents is provided by 
questions such as: “In the last 3 years, how many new or significantly improved 
products or processes has this business introduced on to the market?”  
 
Overall, 51% of respondents to the 2002 survey reported implementation of a new 
product with the innovation rate being lowest for food manufacturers (33%) and 
highest for non-food manufacturers (79%). Process innovation rates were much 
lower with only 21% reporting implementation of a new process in the last 3 
years; this is notably different to the 98/99 survey when 33%29 of enterprises 
reported introduction of new products and the same percentage reported 
introduction of new processes30. Enterprises were also asked about products and 
processes under development. Innovation rates were rather higher for this question 
                                                 
29 The higher innovation rate reported in the 2002 survey (51%) is expected since it was targeted at 
enterprises that conduct R&D. 
30 Future work is required to better understand the way in which New Zealand enterprises respond 
to questions on the number of new products and new processes.  
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with 79% of respondents reporting that they had products or processes under 
development, see Table 16. 
 
Respondents were asked whether new products/processes were new to their 
business, new to New Zealand or new to the world. This question aims to elicit an 
indication of the degree of novelty of the new product/process31. Out of 80 new 
products introduced in the last 3 years, 91% (73) were reported to be new to New 
Zealand and 66% (53) new to the world, see Table 17. The proportion reported to 
be new to New Zealand or to the world is surprisingly high32. One possible 
explanation is that respondents under reported products that were new to their 
business only.  
 
The distribution of the new product/process variables is very skewed; for example 
the top 3% introduced 20% of all new products while the bottom 74% introduced 
only 19%, see Table 18. 
 
                                                 
31 ‘New to the world’ products/processes are assumed to be most novel. 
32 No data is available from the 1998/99 survey on products new to business, NZ, world. Process 
data was collected but was processed inconsistently and so is of little use. 
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Table 16 Innovative Output of Biotech Respondents (2002) 
Industrial Group No. of 
Biotech 
Respondents 
% 
Reporting
Any R&D
% 
Implementing 
New Product 
Last 3 Yrs 
% 
Implementing 
New Process 
Last 3 Yrs 
% with 
products or 
processes 
under 
development
Primary Products 6 83% 67% 17% 67% 
Food 
Manufacturing  
6 83% 33% 17% 67% 
Non-Food 
Manufacturing 
14 100% 79% 43% 93% 
Scientific 
Research  
18 94% 39% 6% 89% 
Tertiary 
Education  
12 100% 42% 17% 75% 
Health Services 
and Other 
5 40% 40% 40% 40% 
Total  61 90% 51% 21% 79% 
Note: percentages should be interpreted with caution because of small cell numbers. 
Source: Marsh (2002). 
  
Table 17 Number of New Products and Processes in Last 3 years (2002) 
 Number of New Products Number of New Processes 
Industrial Group New to the 
Business33 
New to New 
Zealand 
New to the 
World 
New to the 
Business 
New to New 
Zealand 
New to 
the World
Primary Products 21 20 14 1 0 1 
Food Manufacturing  2 1 1 4 4 0 
Non-Food 
Manufacturing 
34 30 19 9 2 2 
Scientific Research  12 11 11 1 0 1 
Tertiary Education  8 8 7 2 2 2 
Health Services and 
Other 
3 3 1 2 0 0 
Total  80 73 53 19 8 6 
Source: Marsh (2002). 
                                                 
33 This is also the ‘total’ number of new products introduced. Products that are ‘new to the world’ 
are also recorded as being ‘new to NZ’ and ‘new to the business’. 
Biotechnology in New Zealand 41 
 
 
 
Table 18 Frequency Distribution for Number of New Products and 
Processes 2002 
Number of 
Products/ 
Processes 
Planned 
New Product 
Last 3 Yrs 
New to 
New 
Zealand 
New 
to 
World 
New Process 
Last 3 Yrs 
0 30 49% 33 52 48 79% 
1 15 25% 13 6 10 16% 
2-5 11 18% 10 1 3 5% 
More than 5 5 8% 5 2 0  
Source: Marsh (2002). 
 
5.2 International Comparisons 
Innovation rate data have been collected in EU and OECD member states since 
199234 but was not systematically collected in New Zealand until 2001. Some data 
are available from an innovation survey commissioned by MORST in 1994. 
Respondents were asked: “how many completely new product lines have you 
introduced in the last 5 years?” It was found that the average company had 
introduced 16 completely new products over that period (Frater, Stuart, Rose, & 
Andrews, 1995, p. 74). This is a significantly higher level than reported by 
biotech respondents, (averaging one new product per enterprise over the last three 
years) although this may be partly attributable to differences in the survey 
populations, question formats and timeframe. 
 
In June 2001, Statistics New Zealand conducted the first economy wide Business 
Practices Survey (BPS). The BPS collected information on three aspects of 
business activity: use of information technology, innovation and management 
practices (Statistics New Zealand, 2002). Key findings included: 
Sixty-eight percent of New Zealand private sector enterprises introduced 
an innovation in the three years ended June 2001. Forty-two percent of 
firms introduced both product and process innovations, while a smaller 
proportion introduced product-only innovations (19 percent), and process-
only innovations (7 percent). 
The proportion of New Zealand firms that introduced an innovation 
increased with business size. Eighty percent of large firms (those with 50 
                                                 
34 The European Community Innovation Surveys (CIS) began in 1992 and were repeated in 1996 
and 2001(Archibugi, Cohendet, Kristensen, & Schaffer, 1994; Eurostat, 2001), for details of 
OECD innovation surveys see Muzart (1998). 
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or more full-time employees) introduced an innovation, compared with 66 
percent of small firms (those with 6 to 19.5 full-time employees). 
The manufacturing sector had the highest rate of innovation in the 
economy (79 percent of firms). In particular, 87 percent of firms in the 
petroleum, coal and chemical manufacturing industry introduced an 
innovation. Fifty-six percent of firms in the primary sector introduced an 
innovation, and 67 percent of firms in the services sector introduced an 
innovation. 
The OECD has used ‘the share of firms introducing at least one new or improved 
product or process onto the market over a given period’ to compare the innovative 
output of firms in different member countries. The OECD average proportion of  
manufacturing firms that introduced a new product or process in 1994-96  was 
56% (data from 21 OECD members). For firms with 20-49 employees the share 
was significantly lower, averaging 41% of firms (OECD, 2001, p. 174). Statistics 
New Zealand (2002) reports that: 
the level of innovative activity carried out by New Zealand enterprises is 
at least equal, if not higher, than that indicated in a survey of European 
Union (EU) countries. The level of innovation in the New Zealand 
manufacturing and services sectors (the EU survey excluded the primary 
sector) was higher than that of all EU countries.  
Review of the innovation literature suggests that Statistics New Zealand should be 
cautious of claiming that “the level of innovation in the New Zealand 
manufacturing and services sectors …was higher than that of all EU countries” on 
the basis of one set of survey results. For example Tether (2001, p. 17) reports that 
comparisons between sectors and between countries are problematic: 
For although the aim of CIS is to provide comparable statistics (between 
countries and sectors), there are doubts as to whether the findings are 
comparable. Are services really less likely to be (technological) 
innovators than manufacturers? – perhaps they are merely less likely to 
recognize themselves as innovators. Statements about the proportion of 
innovators also say nothing about the intensity of innovation activities, 
which tend to be unevenly distributed among firms and groups of firms. 
Meanwhile the threshold of what is considered an ‘innovation’ may vary 
between sectors and countries. A small change may not qualify as an 
innovation in a sector where change is routine or continuous, but may be 
considered an innovation where change is rare. 
New Zealand government, business and the media have been heavily preoccupied 
with the word innovation over the last few years. The word tends to be used in a 
loose sense and it is reasonable to assume that many respondents will have been 
predisposed to regard quite small changes to their business as ‘innovations’. A 
detailed investigation into the kinds of activities that respondents in New Zealand 
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and other countries regard as being innovations is required before definite 
conclusions can be reached on the relative innovative output of New Zealand 
firms. 
 
The mean innovation rate for a group of small OECD countries that New Zealand 
might wish to emulate35 was 62% for all firms and 50% for small firms. The 
1998/99 biotech survey found that 45% of respondents had introduced an 
innovation in the previous 3 years, while the 2002 survey found that 54% were 
innovators. The low level of reported innovation, relative to the BPS may, in part, 
be explained by the nature of the sector where a high proportion of enterprises36 
are engaged in scientific research or higher education where the main outputs may 
be intellectual property in the form of journal publications and patent applications. 
It is also possible that enterprises in a research-intensive sector such as biotech are 
less likely to classify changes as innovations, compared to less research-intensive 
sectors. 
 
Further work is required before definite conclusions can be reached on the relative 
innovative output of New Zealand biotech firms – although the evidence reviewed 
above suggests that New Zealand biotech firms do not have a particularly high 
rate of new product or process development relative to other New Zealand sectors 
or to other countries. 
 
                                                 
35 Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Portugal, Sweden, Switzerland 
36 38% of institutions responding to the 2002 survey fell into these two groups (25% for the 1998/9 
survey). 
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6 Patenting and the Stock of Ideas 
The use of patents as economic indicators has been well established for many 
years37. Ideally we might hope that patents would provide an indication of the rate 
at which the production possibilities frontier is shifted outward (Griliches, 1990, 
p. 1699). In practice they are most commonly used as indicators of innovative 
activity, although more strictly defined they are indicators of invention not 
necessarily leading to innovation.  
 
Patent statistics have also been used to test Romer’s (1990) model of endogenous 
technological change. In this model productivity growth is driven by allocation of 
resources to an ideas-producing sector and ideas sector productivity must increase 
proportionately with the stock of ideas already discovered. Patent statistics have 
been used as an indicator of the stock of ideas by Porter and Stern (2000), among 
others. There is also a rapidly increasing literature in the biotechnology area based 
on analysis of patents (Foltz, Barham, & Kim, 2000; Joly & de Looze, 1996; Malo 
& Geuna, 1999; McMillan, Narin, & Deeds, 2000). 
 
Analysis of New Zealand patenting activity in biotechnology was carried out by 
the author, using international applications published in the Patent Cooperation 
Treaty (PCT) Electronic Gazette. The PCT provides for the filing of an 
international application to have the same effect as a national application in each 
of the contracted states designated in the application (OECD, 1994, p. 19); it thus 
provides a useful measure of international patenting activity. Use of applications 
data provide a more immediate picture, since it can take up to five years from the 
first application for a patent to be granted.   
 
Methodology based on Engelbrecht and Darroch (1999) was used to compare 
New Zealand’s rate of patenting with G7 and a reference group of small high-
income OECD countries (see Table 19 and Figure 10). For the purposes of this 
analysis the International Patent Class C12N is assumed to provide a good 
indication of the level of modern biotech activity. 
                                                 
37 See Griliches (1990) for a comprehensive survey. 
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Table 19 New Zealand and OECD Patenting Rates in Biotechnology 
 1997-99 2000-02 % Change 
97/99-00/02 
1998-2002 
OECD (18 Countries) 3.9 5.9 51% 5.3 
G7 3.9 5.9 52% 5.3 
Small Countries38 4.4 6.1 40% 5.5 
Australia 3.5 4.7 34% 4.1 
New Zealand 2.0 4.8 145% 3.7 
 Source: Original analysis of PCT database by the author. 
Notes: Patenting rates are for class C12N per million population per year.  
 
New Zealand’s rate of modern biotech patent applications over the five years to 
the end of 2002 was 3.7 per million of population, per year. This is below the 
average for the G7 (5.3) and for a reference group of small, developed OECD 
economies (5.5). Patent application rates range from a high of 15.2 for Denmark 
to a low of 0.5 for Italy. Overall New Zealand ranks eleventh out of 18 with a 
patenting rate above that found in France and Japan. However New Zealand’s 
performance is disappointing compared to other small countries with strong 
primary industries that it might hope to emulate e.g. Denmark (15.2), Switzerland 
(10.9), Netherlands (5.5), Australia (4.1).  
 
Comparison of the three-year periods 1997-99 and 2000-02 reveals an average 
increase in patenting rates of 51%. Patent application rates increased in all 
countries, with the rate of increase varying from 18% in the Netherlands to 145% 
in New Zealand (see Figure 9). New Zealand has increased its performance 
relative to the OECD and Australia; although the rapid change in patent 
application rates may, in part reflect an increased propensity to patent caused by 
institutional change in the science system.   
                                                 
38 Australia, Belgium, Denmark, Finland, Ireland, Netherlands, NZ, Norway, Sweden, Switzerland 
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Country Codes (in patent rate order): Denmark (DK), Switzerland (CH), United States (US), 
Netherlands (NL), Belgium (BE), United Kingdom (GB), Canada (CA), Sweden (SE), Australia 
(AU), Germany (DE), New Zealand (NZ), Japan (JP), Austria (AT), Finland (FI), France (FR), 
Norway (NO), Ireland (IE), Italy (IT). 
 
  Source: Original analysis of PCT database by the author. 
 
 
Figure 9 New Zealand C12N Patent Applications 
Figure 10 Comparison of International Biotech Patent Application Rates 
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Figure 10 uses log scales to compare international C12N patenting rates, adjusted 
for the population of each country. It can be seen that this produces a surprisingly 
good fit with 75% of the variation in applications being explained by population 
size. Based on this analysis New Zealand is very close to the trend line; its C12N 
patent rate is close to the expected value, after adjusting for population size. There 
are few real outliers, although Denmark and Switzerland have a rather higher 
patenting rate than expected, while the rate for Italy and Ireland is lower than 
expected. 
 
A breakdown of New Zealand patent applications by organisational type indicates 
that C12N patenting activity is heavily concentrated in a small number of 
organisations. Five organisations39; a private company (Genesis), two CRIs 
(AgResearch and HortResearch) and two universities (Auckland and Otago) 
accounted for 75% of patenting activity over the five years to the end of 2002. 
Figure 11 illustrates the distribution of patenting activity across the main 
organisational types. It can be seen that joint patents accounted for 16% of the 
total, with collaborations between CRIs and private enterprises being most 
common. 
 
 
 
 
 
 
 
 
 
Source: Original analysis of PCT database by the author. 
Notes: Joint patent applications were also observed within organisational types e.g. 
between universities and between different private enterprises. 
 
                                                 
39 Either individually or in partnership with others. 
Figure 11 No. of Patent Applications 1998-2002, by 
Organisational Type 
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Organisations participating in the 1998/99 and 2002 biotech survey were asked 
whether they had made ‘biotech related patent applications’ and so reported on a 
wider range of patents falling under C12N and several other patent classes. As 
would be expected from the data presented above, patenting activity was 
concentrated in a relatively small number of organisations, see Table 20. 
Table 20 Patent Applications 
 1998/99 2002 
No. of Respondents 180 61 
No. respondents making patent 
applications in last year 
21 22 
Total No. of patent applications 56 69 
Sources: Marsh (2001a; 2002). 
 
 
7 Partnerships and Alliances 
7.1 Data from the 1998/99 Survey 
Respondents to the 1998/99 biotech survey were asked40 about partnerships and 
alliances for biotechnology activity over the last 3 years. Further questions 
focussed on the purpose of any alliances and the types of New Zealand and 
overseas organisations involved.  
 
52% of biotech respondents reported a partnership/alliance with a total of 30341 
different organisation types; this suggests that the 93 respondents that had 
alliances had an average of at least three partners each.  
 
The proportion of respondents reporting a biotech alliance varied markedly 
between industry groups from 100% in tertiary education to a low of 18% for 
local government. Overall 48% reported at least one New Zealand alliance while 
30% reported an overseas alliance. Overseas alliances were most common in the 
tertiary education, non-food manufacturing and scientific research groups, see 
                                                 
40 “In the last 3 years did this business have any partnership/alliance for undertaking biotechnology 
activity (research or production)?” 
41 Respondents were not asked how many different organisations they had partnerships with. Data 
was collected on the different types of organisations with which they formed alliances e.g. CRIs 
businesses, universities etc both in NZ and overseas.  
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Figure 12. A breakdown of alliance frequency by biotech category reveals that 
90% of MBEs reported alliances falling to 42% for MBUs and 24% for TBUs. 
 
The most commonly reported alliance purposes were product or process 
development; reported by 81% of respondents who had an alliance and 
clinical/field trials (48%). 13% reported alliances for the purpose of undertaking 
basic research42, see Figure 13. 
 
 
                                                 
42 Based on answers in the ‘other’ category - this may be an underestimate since the questionnaire 
did not include a basic research option. 
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Source: Marsh (2001a, p. 17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Marsh (2001a, p. 18) 
 
 
 
Figure 12 Percentage of Respondents Reporting Biotech Alliances (1998/99) 
Figure 13 Purpose of Biotech Alliances (1998/99) 
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7.2 Data from the 2001/02 Survey 
84% of respondents to the 2001/02 survey reported a biotech partnership or 
alliance with a total of 406 different organisations. The higher incidence of 
alliances compared to the 1998/99 survey was expected, given the different 
characteristics of the survey population. While most enterprises (88%)  reported 
up to 10 alliances; two organisations reported 90 and 50 different alliances 
respectively43, see Table 21.` 
 
Table 21 Frequency Distribution for No. of Alliances 
Number of Alliances  
1-3 51% 
4-10 37% 
10+ 12% 
Source: Marsh (2002). 
 
The proportion of respondents reporting a biotech alliance was high in all industry 
groups, varying from 100% in the tertiary education group to 40% for ‘health 
services and other’ (a small group including some enterprises that did not conduct 
significant R&D). 
 
Overall 62% reported at least one New Zealand alliance while 41% reported an 
overseas alliance. Overseas alliances were most common in the tertiary education, 
and scientific research groups, see Figure 14.  
 
The most commonly reported alliance purposes were product/process 
development – reported by 82% of respondents who had an alliance and basic 
research (74%), see Figure 15. A higher proportion of alliance partners were 
engaged in basic research than reported in the 1998/99 survey. This can be 
explained by differences in the survey population and the lack of a specific 
question about basic research in the earlier survey. 
 
                                                 
43 A university ‘sub-unit’ with around 100 staff conducting R&D reported 90 different 
‘partnerships or alliances’; many of these are ‘academic collaborations’. 
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Source: Marsh (2002) 
 
 
 
 
 
 
Source: Marsh (2002). 
Note: Percentages expressed as % of number of enterprises with an alliances. 
Figure 14 Percentage of Respondents Reporting Biotech Alliances (2002) 
Figure 15 Alliance Type and Purpose 
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A high proportion of alliances had characteristics that would indicate active and 
substantive partnerships. 84% of respondents (with alliances) reported that at least 
one alliance involved ‘active participation by both parties’, 76% had alliances 
involving ‘contracting in or out’ and 48% had alliances involving ‘staff working 
or training at partner locations’, see Figure 15. 
 
Respondents were asked to report on the key characteristics of their three most 
important partnerships; 55% of these involved New Zealand partners, followed by 
19% USA, 14% Europe, 9% Australia44. Figure 16 summarises data on the 
percentage of respondents with at least one alliance in different countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Marsh (2002). Notes: Percentages expressed as % of number of enterprises with 
an alliance. International (Any) excludes Australia.  
 
Most alliance partners were universities/polytechnics (32%), larger firms (27%), 
smaller firms (17%) or CRIs (16%)45.  
 
                                                 
44 Based on data for 117 different partnerships/ alliances, from 50 respondents with partnerships/ 
alliances. 
Figure 16 Percentage of Respondents with Alliance Partners, by Country 
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Partnerships were established between 1956 and 2001. 54% of partnerships had 
been established in the last 3 years; providing some support for the observation 
that partnership activity has increased in recent years46. 
 
Respondents were asked to rate ‘partnership outcomes to date’; 50% were 
described as ‘very productive’ and 44% as ‘somewhat productive’. Only 6% were 
reported to be ‘not very/not at all productive’, see Table 22. The relationship 
between perceived alliance productivity and other variables is explored in 
Chapter 6.  
Table 22 Alliance Outcomes 
Industrial Group Very 
Productive
Somewhat 
Productive
Not Very 
Productive
Not at all 
Productive 
No. of 
Alliances
Primary products 60% 40% 0% 0% 5 
Food manufacturing 56% 33% 0% 11% 9 
Non-food manufacturing 52% 41% 7% 0% 27 
Scientific research 52% 43% 2% 2% 44 
Tertiary education 48% 45% 7% 0% 29 
Health services & other 0% 100% 0% 0% 3 
Total 50% 44% 4% 2% 117 
Source: Marsh (2002). 
Note: Based on up to three of ‘the most important partnerships’ per respondent. 
 
                                                                                                                                     
45 See footnote 44. 
46 This result is based on a subset of the data; respondents reported year of formation for only 50 
out of 117 of the ‘three most important partnerships/alliances’. 
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8 Information Sources 
One of the more detailed investigations into information sources for technological 
learning in New Zealand was carried out by the Foundation for Research Science 
and Technology (FRST) in 1996/9747. The review sought to identify ways in 
which government could accelerate and enhance technological learning. It was 
based on 500 personal interviews and 666 mail survey responses. The review 
highlighted widespread concerns about the availability of science and technology 
information to users: 
Many concerns about access to information relate to the behaviour of 
science providers (especially CRIs), often in relation to their intellectual 
property, commercial confidentiality and charging policies…The Review 
identifies a wide and pervasive trend among user and other stakeholder 
groups to be more restrictive and less willing to share information. This 
trend is occurring even in sectors such as agriculture and horticulture with 
long traditions of open and free exchanges of information and new 
ideas…There is a view that CRIs (or at least some CRIs) are ignoring 
small companies in favour of building more commercially profitable 
relationships with larger businesses (Hodgson et al., 1998, p. 23-4). 
The review report describes sources and forms of technological learning and 
‘learning concerns’ separately for 233 ‘technological learning groups48’. The 
review could usefully have identified a smaller number of broad categories based 
on key characteristics of technological learning. Such categories might then have 
been related to industrial groups, learning concerns and other variables. 
 
Unfortunately very little aggregate analysis was ever reported49. Qualitative data 
from selected technological learning groups associated with biotechnology have 
been used to create Table 23. Unfortunately the qualitative approach adopted in 
the report does not allow any conclusions to be drawn on the relative importance 
                                                 
47 Reported in Hodgson, P., Howe, J., Saunders, R., & Winsley, P. (1998). 
48 “The taxonomy of 233 technological learning groups was developed over time … with this 
taxonomy being “grounded” in the experiences and perceptions of research end users, rather than 
being determined a priori”(Hodgson et al., 1998, p. 9). 
49 The decision not to aggregate was defended by the authors; “the level of detail achieved in 
producing the 233 technological learning group summaries at an end user organisational level 
means it is more appropriate to present the complete material in Annex 6 rather than attempt to 
generalise the results of the Review in a way that would mask the differentiated nature of learning 
and diminish the usefulness of the review”(Hodgson et al., 1998, p. 6). 
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of different information sources. Furthermore data source coverage in different 
technological groups appears to be patchy; for example private laboratories might 
be expected to make some use of trade literature and equipment suppliers. This 
patchiness may perhaps be a consequence of the qualitative methods used in the 
survey. 
Table 23 Technological Learning Sources 1997 
Technological 
Learning Source 
Animal 
Vaccines 
and 
Remedies 
Drugs and 
Medicine 
Manu-
facturers 
Dairy Food 
Product 
Companies
Private 
Lab-
oratories 
Private 
R&D 
Companies
Customers 9  9 9 9 
R&D Staff 9 9 9 9 9 
Senior Management 9  9 9 9 
Journals 9 9  9 9 
Trade Literature 9 9 9   
CRIs 9 9   9 
Universities 9  9 9 9 
Overseas research 
institutes 
 9    
Overseas Licences  9    
Suppliers (raw 
materials) 
 9 9   
Suppliers 
(equipment) 
 9 9  9 
Research 
Associations 
 9 9   
Competitors   9 9  
Conferences and 
Trade Fairs 
  9   
Source: Hodgson et al., (1998). 
 
Statistics New Zealand’s 2001 Business Practices Survey provides some useful 
information on the sources of ideas and information used in innovation. One 
question related to whether innovations relied on internal or external information 
sources, or both; 
product innovations relied more on external resources than process 
innovations. Twenty-one percent of product innovators relied on external 
resources compared with 8 percent of process innovators. Process 
innovators relied mainly on internal resources (55 percent), while the 
proportion of product and process innovators relying on a combination of 
internal and external resources was about the same (just under a third). 
 
The BPS also provides data on the percentage of innovators making use of 
different information sources, see Figure 117. It can be seen that the most used 
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sources were ‘competitors’, ‘books, trade journals and conferences’ and ‘industry 
associations’. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Statistics New Zealand (2002, p. 23) 
 
Data on the relative importance of these different sources in all New Zealand 
firms can be compared with the 2002 Biotech Survey50, see Figure 18. Biotech 
respondents ranked the research institutions, universities/polytechnics and ‘books, 
trade journals and conferences’ more highly than the average for BPS 
respondents, while BPS respondents ranked industry or employer associations 
more highly. 
 
                                                 
50 Mean scores were created based on Statistics New Zealand category ‘very important’=5, 
‘somewhat important’=3, ‘not important’=1. Category descriptions across the two surveys do not 
exactly match. 
Figure 17 Sources of Information for Innovative Business 
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Figure 18 Comparison of Information Sources, BPS and Biotech Survey 
2002 
 
 
 
 
 
 
 
 
 
 
 
 
Sources: Marsh (2002) and Statistics New Zealand (2002). 
 
Table 24 Information Sources, Biotech Survey 2002 
  
Low       High Not 
Applicable 
Mean 
Score 
  1 2 3 4 5     
Own staff or staff in parent/subsidiary  0 2 10 16 27 5 4.2** 
Hiring new staff with required ‘know-how’ 3 7 12 15 10 11 3.5* 
Personal contacts with others 2 2 8 19 26 2 4.1** 
Conferences/workshops/trade shows 3 7 13 25 11 0 3.6* 
Other Firms 8 7 19 13 4 7 3.0 
Crown Research Institutes 13 11 16 8 7 4 2.7 
Other Research Organisations 5 10 23 11 6 4 3.1 
Universities, Polytechs, research networks 6 9 18 13 10 3 3.2 
Hospitals 23 9 7 2 1 17 1.8 
Government departments/agencies 24 11 13 2 1 8 1.9 
Professional/industry associations 15 16 14 3 2 6 2.2 
Other organisations     1     5 3.0 
Academic journals and trade publications 0 3 10 22 25 0 4.2** 
Library/literature search 2 5 8 24 20 0 3.9* 
Database retrieval services 5 7 11 15 19 3 3.6* 
Patent disclosures 15 9 7 9 11 8 2.8 
Notes:  The symbols ** mark sources ranked first to third, * marks sources  
 ranked 4th  to  7th.  Modal scores for each source are shaded. 
Source: Marsh (2002).  
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9 Other Factors Affecting Innovative Performance 
The 2001 survey asked respondents to rank a list of factors “that may affect the 
amount of innovation produced by your business”, see Table 25. Many of the 
results are unsurprising; for example ‘quantity of funds available for R&D’ is 
ranked most highly, followed by ‘number and quality of R&D staff’ and 
‘appropriability (ability to profit from the innovation)’. 
 
These mean scores hide some important patterns in the way that respondents 
answered this question. The most controversial question relates to the impact of 
‘one or a few star scientists’; 18 respondents regarded this as being highly 
important (score 5), while 14 clearly disagreed giving this item a score of 1. 
 
Table 25 Factors Affecting Business Performance 2002 
  
Low    High Mean 
Score 
  1 2 3 4 5  
Conditions in your business       
Quantity of funds available for R&D  1 2 9 16 31 4.3** 
Quality of the R&D environment  4 2 9 19 25 4.0 
Number and quality of R&D staff 3 3 5 18 28 4.1** 
One (or a few) ‘Star Scientists’  14 4 8 12 18 3.3 
‘Science push’ or technological opportunity 5 4 16 20 10 3.5 
Quality of links with other organisations in New Zealand 4 8 23 17 7 3.3 
Quality of links with overseas organisations  4 5 11 21 16 3.7 
Ownership of intellectual property 10 8 9 12 19 3.4 
Appropriability (ability to profit from the innovation) 3 5 4 15 31 4.1** 
Links with purchasers or consumers e.g. ‘demand pull’ 6 7 4 18 21 3.7 
Conditions in New Zealand       
Quality/quantity of Basic Science carried out  6 6 13 20 12 3.5 
Quality/quantity of Applied Science carried out  5 6 11 23 12 3.5 
R&D environment e.g. regulations, incentives, attitudes etc 5 5 13 13 20 3.7 
Notes:  The symbols ** mark sources ranked first to third,  
 Modal scores for each source are shaded. 
Source: Marsh (2002).  
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Figure 19 illustrates some of the differences between industrial groups in the 
perceived importance of different factors. Enterprises in tertiary education place 
greater weight on ‘star scientists’ and ‘science push’ and regard ‘appropriability’ 
and ‘demand-pull’ as less important. By contrast, primary product enterprises rank 
‘demand-pull’ and appropriability as being more important. Mean scores for 
manufacturers and scientific research organisations were similar for these four 
factors; perhaps reflecting the importance of commercial incentives for 
organisations in the scientific research category.  
 
Source: Marsh (2002). 
 
 
 
 
Figure 19 Mean Factor Scores by Industrial Group 
Star Scientists
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10 Summary and Conclusions 
10.1 Sector Size and Definition 
Different interpretations of the terms biotechnology and biotechnology sector 
hinder attempts to measure biotech activity in a way that is comparable over time 
and across nations. Size estimates for the New Zealand biotech sector range from 
30 core biotech companies with annual income of the order of $200 million, to 
many thousands of companies having annual production worth several billion 
dollars, when traditional food applications such as cheese, yoghurt and beer are 
included. 
 
The economic literature since the mid 1980s has generally concentrated on 
modern biotechnology and the biotech sector is often taken internationally to refer 
to the population of ‘core’ private sector enterprises that conduct R&D into 
modern biotechnology. In this thesis the modern biotech ‘sector’ is defined as the 
population of private and public sector enterprises that carry out modern biotech 
R&D. Based on this definition, New Zealand’s modern biotech ‘sector’ consisted 
in 1998/99 of approximately 57 enterprises, employing  around 1700 people. Most 
activity was concentrated in universities, Crown Research Institutes (CRI) and a 
small number of private sector companies e.g. Genesis, Virionyx, ViaLactia. 
10.2 International Comparisons 
The OECD has taken the lead in attempting to develop internationally comparable 
statistics on biotechnology. Data on public funding of biotechnology and patents 
were included in its Science, Technology and Industry Scoreboards for 2001 and 
2003 (OECD, 2001, 2003) but the variety of definitions and data collection 
methods make reliable comparisons almost impossible. In the 2003 scoreboard 
New Zealand is reported to put the highest proportional effort into biotech R&D 
(biotech R&D as a proportion of total R&D). This results both from New 
Zealand’s R&D specialisation in the primary sector and from use of a broad 
definition of what constitutes biotech R&D. Not surprisingly, a rather different 
picture emerges in absolute terms with New Zealand’s total biotech GBAORD 
being the third smallest of the 21 countries listed (see section 2.5) 
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A more accurate international comparison can be made with Canada, based on 
data from the Statistics New Zealand biotech survey, since this was closely 
modelled on surveys carried out by Statistics Canada. New Zealand’s biotech 
revenue per million population (NZ$54 million) is rather lower than Canada's 
(NZ$94 million), but the difference is fairly small considering Canada’s higher 
per capita income and proximity to the United States. New Zealand has a rather 
lower mean revenue per biotech firm (NZ$5.3m vs. NZ$8.0m); consistent with 
the predominance of small firms in the New Zealand economy. New Zealand 
appears to have a significantly higher rate of biotech employment. There is some 
evidence that use of biotech processes in New Zealand is at an earlier stage with 
72% being at the R&D stage against 49% in Canada. 
 
10.3 Sector Characteristics 
Enterprises in the modern biotech sector are split fairly evenly between the private 
sector and the public sector. They reported expenditure on biotech of NZ$202 
million and income from biotech of NZ$236 million for 1998/99. This compares 
to enterprise income from all sources of NZ$2.1 billion i.e. biotech provided 
around 11% of income for the 57 enterprises. More recent data indicates that 
annual growth in expenditure may be as much as 20%. 
 
Respondents to the 2002 biotech survey indicated that R&D constituted around 
10% of total expenditure while expenditure on biotech R&D comprised around 
80% of all biotech expenditures. Around 60% of all ‘biotech staff’ were engaged 
in R&D. Respondents spent far more on R&D than the industry average. For 
example the dairy industry is reported to spend around 1% of turnover on R&D, 
while R&D expenditure as a proportion of value added of manufactured products 
was 1.3 percent in 1999/2000 (see section 4.1.2). 
 
The government has been estimated to spend around NZ$127m a year on all 
biotechnology-related research, ranging from genomics to processing of natural 
products. Biotechnology-related research comprised around 15% of total 
government R&D spending in 2000. 
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Data on the age distribution of biotech processes provides useful information on 
the development of the biotech industry over time and may also be compared with 
similar data from overseas. Average age in use in New Zealand is longer than in 
Canada for all but two process categories, possibly because of the lower number 
of new entrants in New Zealand. There are distinct differences between modern 
and older biotechnology processes. Genomics exhibits a typical age structure for a 
recent process; 56% have used this process for 5 years or less, 83% have used it 
for 10 years or less. Extraction/purification/separation is typical of a more mature 
technology; 24% started using this process within the last 5 years (often these are 
new enterprises). A further 24% have been using this process for at least 20 years 
(see section 3.3) 
10.4 Innovative Output 
In June 2001 Statistics New Zealand conducted the first economy wide Business 
Practices Survey (BPS). The BPS collected information on three aspects of 
business activity: use of information technology, innovation and management 
practices (Statistics New Zealand, 2002). Statistics New Zealand (2002) reports 
that: “the level of innovative activity carried out by New Zealand enterprises is at 
least equal, if not higher, than that indicated in a survey of European Union (EU) 
countries”. Review of the innovation literature suggests that Statistics New 
Zealand should be cautious of making such claims on the basis of one set of 
survey results. For example Tether (2001, p. 17) reports that comparisons between 
sectors and between countries are problematic for a number of reasons (section 
5.2). 
 
One indication of the rate of innovation by biotech respondents is provided by 
questions such as: “In the last 3 years, how many new or significantly improved 
products or processes has this business introduced on to the market?” Overall, 
51% of respondents to the 2002 biotech survey reported implementation of a new 
product with the innovation rate being lowest for food manufacturers (33%) and 
highest for non-food manufacturers (79%). Process innovation rates were much 
lower with only 21% reporting implementation of a new process in the last 3 
years; this is notably different to the 1998/99 survey when 33% of enterprises 
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reported introduction of new products and the same percentage reported 
introduction of new processes.  
 
Further work is required before definite conclusions can be reached on the relative 
innovative output of New Zealand biotech firms, although the evidence reviewed 
in section 5.2 suggests that New Zealand biotech firms do not have a particularly 
high rate of new product or process development relative to other New Zealand 
sectors or to other countries. 
10.5 Data on Patenting 
New Zealand’s rate of modern biotech patent applications over the five years to 
the end of 2002 was 3.7 per million of population, per year. This is below the 
average for the G7 (5.3) and for a reference group of small, developed OECD 
economies (5.5). Patent application rates range from a high of 15.2 for Denmark 
to a low of 0.5 for Italy. Overall New Zealand ranks eleventh out of 18 with a 
patenting rate above that found in France and Japan. However New Zealand’s 
performance is disappointing compared to other small countries with strong 
primary industries that it might hope to emulate e.g. Denmark (15.2), Switzerland 
(10.9), Netherlands (5.5), Australia (4.1).  
 
Comparison of the three-year periods 1997-99 and 2000-02 reveals an average 
increase in patenting rates of 51%. New Zealand has increased its performance 
relative to the OECD and Australia; although the rapid change in patent 
application rates may, in part reflect an increased propensity to patent in 
universities and Crown Research Institutes. 
 
Regressing C12N patenting rates against population produces a surprisingly good 
fit with 75% of the variation in applications being explained by population size. 
Based on this analysis New Zealand is very close to the trend line; its C12N 
patent rate is close to the expected value, after adjusting for population size. There 
are few real outliers, although Denmark and Switzerland have a rather higher 
patenting rate than expected, while the rate for Italy and Ireland is lower than 
expected (see section 6). 
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10.6 Biotech Alliances and Other Factors 
Most enterprises (84%) responding to the 2002 biotech survey had at least one 
alliance involving biotech activity, 62% reported at least one New Zealand 
alliance while 41% reported an overseas alliance. Overseas alliances were most 
common in the tertiary education, and scientific research groups. The most 
commonly reported alliance purposes were product/process development; reported 
by 82% of respondents who had an alliance and basic research. Respondents were 
asked to rate ‘partnership outcomes to date’; 50% were described as ‘very 
productive’ and 44% as ‘somewhat productive’. Only 6% were reported to be ‘not 
very/not at all productive’. Further details of biotech alliances are reported in 
section 7. 
 
Section 8  provides data on the main sources of information used by enterprises in 
the biotech sector while section 9 focuses on a range of other factors that affect 
innovative performance. There are some significant differences between industrial 
groups in the perceived importance of different factors. Enterprises in tertiary 
education place greater weight on ‘star scientists’ and ‘science push’ and regard 
‘appropriability’ and ‘demand-pull’ as less important. By contrast, primary 
product enterprises rank ‘demand-pull’ and appropriability as being more 
important.  
 
This paper has provided a detailed description of the New Zealand biotech sector 
based on data collection and analysis carried out by Marsh (2001a; 2002) and a 
review of secondary sources. This description sets the scene and provides context 
for a study of the determinants of innovation – see Marsh (2004). Prior to this 
analysis our knowledge of most sector parameters was very limited or completely 
lacking. There is a need for policy makers to make more use of the available data, 
rather than continuing to use less reliable estimates produced by organisations that 
have a vested interest in exaggerating the size of the sector.  
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